Roche Holding AG (ROG.SW)
| Previous close | 232.10 |
| Open | 232.40 |
| Bid | 234.20 x 0 |
| Ask | 234.40 x 0 |
| Day's range | 232.30 - 235.60 |
| 52-week range | 212.90 - 293.05 |
| Volume | |
| Avg. volume | 1,487,011 |
| Market cap | 189.368B |
| Beta (5Y monthly) | 0.16 |
| PE ratio (TTM) | 16.36 |
| EPS (TTM) | 14.32 |
| Earnings date | 25 Jul 2024 |
| Forward dividend & yield | 9.60 (4.14%) |
| Ex-dividend date | 14 Mar 2024 |
| 1y target est | 271.42 |
ZacksPharma Stock Roundup: JNJ, MRK M&A Deals, SNY, RHHBY Drugs' Priority Review & More
J&J (JNJ) and Merck (MRK) announce the acquisitions of private biotechs. The FDA grants Priority Review tags to Sanofi's (SNY) and Roche's (RHHBY) regulatory applications.
ZacksRoche's (RHHBY) Inavolisib NDA Gets FDA Priority Review Tag
The FDA grants priority review to Roche's (RHHBY) NDA for the inavolisib combination regimen for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.
Business WireFDA Grants Priority Review to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
SOUTH SAN FRANCISCO, Calif., May 29, 2024--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application and granted Priority Review to inavolisib, an investigational oral therapy, in combination with palbociclib (Ibrance®) and fulvestrant. The inavolisib-based regimen was evaluated in adult patients with PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth fa
